newsfilter
← Latest News
ACCESS Newswire·

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has applied to